Shingles Vaccine Market By Vaccine Type (Recombinant Shingles Vaccine, Live Attenuated Shingles Vaccine), By Vaccine Composition (Monovalent Vaccines, Combination Vaccines), By Immunization Type (Preventive Vaccination, Therapeutic Vaccination), By Route of Administration (Intramuscular (IM), Subcutaneous (SC)), and By End User (Hospitals, Specialty Clinics, Vaccination Centers, Homecare Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Shingles Vaccine Market in the coming years?

The Shingles Vaccine Market accounted for USD 4.91 Billion in 2024 and USD 5.69 Billion in 2025 is expected to reach USD 24.79 Billion by 2035, growing at a CAGR of around 15.86% between 2025 and 2035. The shingles vaccine market is comprised of the industry dealing with developing, producing, and selling the vaccine that prevents a painful skin rash called shingles that is caused by the varicella-zoster virus, gaining new life. The most important players in this market today are those producing vaccines that target the older population and those with defective immune systems, including Shingrix and Zostavax. Increasing education regarding complications of shingles and the rising ageing populations are some of the factors that lead to increasing demand for these vaccines. Further, the development of vaccine technology and government-funded immunisation are also growth factors in the market globally.

What do industry experts say about the Shingles Vaccine market trends?

“The recombinant zoster vaccine (RZV) is a major advancement in shingles prevention, providing over 90% protection even in older adults. It’s a critical tool for reducing complications like postherpetic neuralgia.”

• Dr. Kathleen Dooling, MD, MPH – Medical Officer, CDC’s Division of Viral Diseases

“The shingles vaccine is one of the most effective vaccines for older populations, significantly lowering both the incidence and severity of herpes zoster. It represents a public health success in adult immunization.”

• Dr. William Schaffner, MD – Professor of Preventive Medicine, Vanderbilt University Medical Center

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Shingles Vaccine market?

Can rising awareness about shingles complications drive vaccine adoption?

Growing awareness of shingles and its complications will be a major motivator to promote vaccination adoption, especially among older adults. Since the varicella-zoster virus is the cause of shingles, which can be very dangerous due to postherpetic neuralgia, which is a long-term nerve pain syndrome. The CDC reports there is approximately a 1 in 3 chance of developing shingles in the U.S., and the risk increases with age. Adults aged 50 and older should be vaccinated to decrease such complications. The percentage of adults aged 60 and over who received the shingles vaccine increased from less than 7% in 2008 to over 34% in 2018 as the value of this vaccine is better understood.

Recommendations of healthcare providers and better levels of health literacy are also contributors to an increase in acceptance. The severe pain associated with shingles is being brought out through educational campaigns that are influencing increased uptake of the vaccine as more people become aware that the vaccine will help prevent shingles and its associated pain. Further, improved access to vaccines via healthcare systems and pharmacies has made vaccines easy for individuals. Further public health work should target underserved segments of the population and increase the general level of vaccination.

Does government immunization support enhance shingles vaccine market growth?

Immunisation by the government is another effective strategy for increasing the market of the shingles vaccine since the government can enhance access to the vaccines and lower prices due to its position as a payer. The CDC advises that adults over 50 years of age should be vaccinated against shingles and participate in Medicare Part D. Medicare Part D has dramatically increased adult vaccinations.

In such a way, the publicly funded initiatives in such countries as Canada have resulted in observable drops in shingles cases and complications. These programmes increase the level of awareness and the number of people willing to be vaccinated against shingles and save on healthcare expenditure due to the avoided shingles-related hospitalisation. Moreover, government campaigns are usually accompanied by outreach in education, which helps alleviate vaccine hesitancy and boosts acceptance.

Manufacturers are also induced by the public financing to inject funds into the research and development of vaccines because the demand remains steady. The international health organisations partner with the government to build up the immunisation infrastructure and increase access to the underserved populations. Overall, state support has a direct influence on increasing the scale of the market, ensuring a high level of adoption of its products and promotion, as well as achieving healthy population results.

Are vaccine side effects causing hesitation among potential recipients?

The fears of side effects are a major factor with regard to the lack of willingness among the potential recipients of the shingles vaccine. As stated by the CDC, the more common side effects found after taking the recombinant shingles vaccine (Shingrix) are pain, redness, and swelling around the place of injection, coupled with fatigue, muscle ache, and fever.

Although these effects are usually quite mild (mild to moderate) in nature, lasting only a few days, approximately 1 person out of 5 has side effects that may temporarily impair daily functioning. This may discourage people, particularly the aged population, from using the recommended two-dose regimen.

Data gathered by CDC surveys indicate that fear of side effects is one of the major factors contributing to the refusal or postponement of vaccines. Healthcare providers must communicate clearly with patients to reassure them about the safety and efficacy of the vaccine to increase their vaccination and limit complications connected to shingles.

How might developing countries expand shingles vaccine penetration soon?

The countries with low penetration of the shingles vaccine can remedy the situation by creating awareness about it and incorporating it into national immunisation schedules. As an example, an area such as China reveals that, in spite of the presence of the shingles vaccine, many older adults have not received it because of limited knowledge and access, and only about 10% of the potential demographic have been vaccinated. Advertisements that inform adults aged above 50 about shingles and its vaccination have been observed to have improved awareness and acceptance of the vaccine, as included in some health department reports of other countries.

Government-sponsored healthcare coverage can help by subsidising the price of the vaccine and lowering access barriers, as evidenced by the situation in Poland, where partial insurance coverage succeeded in enhancing access to the vaccine among the elderly. It is also essential to strengthen healthcare infrastructure to deliver vaccines in rural/underserved locations. By emphasising education, cost-effectiveness, and accessibility, developing nations can incorporate a significant change in vaccination rates and minimise the occurrence of shingles complications among older generations.

Will partnerships with healthcare providers accelerate vaccination programs worldwide?

Ties with healthcare providers play a central role in the faster pace of shingles vaccination programmes globally. When medical workers promote and actively conduct the shingles immunisation, the vaccination is greatly promoted. As an example, respondents at the U.S. Centers for Disease Control and Prevention (CDC) affirmed that moral plans to combat shingles were at approximately 34% of all individuals over the age of 60 as of 2021, with higher numbers seen with the availability of primary care providers.

The National Shingles Vaccination Program in Australia, which liaises with general practitioners, attained approximately 75% of the vaccination coverage of the targeted older adult population within a few years. Such collaborations can address some of the more widespread obstacles that include vaccine hesitancy, awareness, and accessibility.

By coupling the shingles vaccination to general healthcare opportunities and capitalising on the resources of trusted provider-patient relationships, governments can increase the reach of information and vaccination. This partnership model will ensure that people are vaccinated on time, the number of shingles cases will decrease, and the healthcare systems around the world will be spared strain.

What are the key market segments in the Shingles Vaccine industry?

Based on the Vaccine type, the Shingles Vaccine Market is classified into Recombinant Shingles Vaccine and Live Attenuated Shingles Vaccine. The prominent and largest segment in the market of shingles vaccines is the Recombinant Shingles Vaccine (RSV). This superiority is fuelled by the fact that it is more efficacious, particularly among elderly adults, and its protective immunity lasts longer than that of the Live-Attenuated Shingles Vaccine (Zostavax). Non-live formulations of SV, including Shingrix, are also available, which is ideal in immunocompromised patients – an increasingly important patient group. Its market leadership capabilities have also been hastened by strident recommendations by health-related authorities such as the CDC, as well as its broader acceptance on a global scale. Owing to this, RSV has the largest market share and has sustained growth in this area as well.

Based on the Vaccine Composition, the Shingles Vaccine Market is classified into Monovalent Vaccines and Combination Vaccines. The prominent and dominant segment in the shingles vaccine market is monovalent vaccines. This is because shingles vaccines only deal with varicella-zoster, the virus that causes shingles. Monovalent vaccines are also very specific and powerful. Combination vaccines, which cover a variety of different illnesses, are not as widespread in this market, as shingles vaccinations are a niche product. The popularity of monovalent vaccines, such as Shingrix, is evidence of their efficacy, safety, and selectivity, and ensures that they are in a dominant position in the market.

Which regions are leading the Shingles Vaccine market, and why?

The North American shingles vaccine market is dominant due to several factors. A large ageing population is one of the factors contributing to the increased demand for the vaccination since the older population is at a higher risk of the disease. Moreover, an extensive healthcare infrastructure and the available awareness about the advantages of vaccination ensure a greater uptake of the vaccine in question. Insurance coverage and vaccinations, which are strongly supported by the government, are also spearheads towards immunisation. Further, the availability of giant pharmaceutical firms making significant investments into research and development guarantees the presence of worthy and efficient vaccines. Significant influence is also made by the high spending on healthcare and the availability of medical services to people.

Favourable regulations facilitated the flow of new vaccines in the market, which enhances market growth. Outreach and vaccines are also being adapted to reach more people by ensuring the needs of the diverse populations are being met through public-private partnerships. Adopting digital health programmes and expert data tracking tools aids in tracking the COVID-19 vaccine coverage and efficacy. A proactive attitude towards vaccination is encouraged by high educational and health literacy rates among the population.

The Asia Pacific shingles vaccine market is growing due to various reasons. A high rate of population growth, particularly among old people, who are most susceptible to shingles, makes demand high. The factors that further stimulate market growth are the rise of healthcare awareness and the enhancement of access to vaccination programmes within the countries of Japan, China, and Australia, among others. Governments and the private sector are investing in immunisation infrastructure, and the costs of vaccines are becoming reasonable and easily accessible. Besides, an increase in chronic diseases and immunocompromised conditions in the region points to the necessity of prevention of such conditions, like shingles immunisation.

Improved development rates and spending on healthcare are also factors in economic growth. Assistance in market growth by technological refinements in the production of vaccines and market strength in regional partnerships with international drug companies is also playing its part. Where urbanisation is ongoing, the area is also experiencing a better healthcare delivery system to facilitate mass immunisation.

What does the competitive landscape of the Shingles Vaccine market look like?

The shingles vaccine market is currently dominated by industry titans like GSK and Merck, but as more biotechnology companies like Dynavax, Moderna, and CureVac begin clinical trials, competition is predicted to grow. GSK has further strengthened its position with the introduction of a preloaded syringe of its vaccine, which is simpler for healthcare professionals to execute. Dynavax announced positive phase II/III data on its experimental vaccine, demonstrating that it induced immune responses similar to those of current products and also had fewer adverse effects – capturing investor and regulatory attention.

The other opportunity that Moderna has gone through is with the development of its shingles vaccine, indicating a long-term viability in the segment. Recent findings that shingles vaccination keeps people out of the hands of dementia and heart diseases are pushing a wider interest in the field of public health, and this provides a potential growth in market demand. With both veteran pharma and nimble biotech companies developing next-generation formulations, the paradigm is shifting to safer, longer-acting, and worldwide-scalable formulations.

Shingles Vaccine Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Shingles Vaccine industry?

• In July 2025, the U.S. FDA approved a new prefilled syringe presentation of GSK’s Shingrix® (Recombinant Zoster Vaccine, RZV), which simplifies administration by eliminating the need to reconstitute antigen powder and adjuvant vials, making the process easier for healthcare providers while preserving its proven effectiveness.

Report Coverage:

By Vaccine Type

• Recombinant Shingles Vaccine
• Live Attenuated Shingles Vaccine

By Vaccine Composition

• Monovalent Vaccines
• Combination Vaccines

By Immunization Type

• Preventive Vaccination
• Therapeutic Vaccination

By Route of Administration

• Intramuscular (IM)
• Subcutaneous (SC)

By End User

• Hospitals
• Specialty Clinics
• Vaccination Centers
• Homecare Settings

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• GlaxoSmithKline (GSK)
• Merck & Co., Inc.
• Pfizer Inc.
• Moderna Inc.
• Dynavax Technologies
• Curevo Inc.
• GeneOne Life Science
• Jiangsu Recbio Technology Co., Ltd.
• SK bioscience
• CanSinoBIO
• Changchun BCHT Biotechnology Co.
• Vaccitech
• Valneva SE
• Bavarian Nordic
• Johnson & Johnson

Frequently Asked Questions (FAQs)